{
    "hands_on_practices": [
        {
            "introduction": "In pediatric practice, managing benign, self-limited conditions like molluscum contagiosum demands more than just identifying an effective therapy; it requires a patient-centered approach. The optimal management plan must carefully balance the potential benefits of treatment against the risks of physical and psychological harm. This exercise  challenges you to integrate multiple variables—lesion burden, comorbid conditions like atopic dermatitis, and a child's procedural anxiety—to select a strategy that prioritizes the patient's overall well-being.",
            "id": "5171563",
            "problem": "A child presents with molluscum contagiosum, a self-limited infection caused by Molluscum contagiosum virus (a poxvirus) and characterized by dome-shaped, umbilicated papules that commonly resolve spontaneously in immunocompetent hosts. The clinician must decide among three classes of management: home or in-office topical therapies, office-based procedural removal, or no lesion-directed treatment with supportive care. The following scenario is observed.\n\nA $6$-year-old immunocompetent boy with a history of atopic dermatitis has approximately $N=36$ discrete molluscum papules scattered over the trunk and flexural areas, with $S$ including $2$ small lesions on the cheek and no genital involvement. His parents report pruritus and intermittent excoriation. The child exhibits high procedural anxiety, quantified by a numerical rating scale $A=8/10$ for fear of needles, freezing, and surgical instruments, and has previously struggled to tolerate venipuncture and vaccinations without significant distress.\n\nUsing core facts about molluscum contagiosum, including the natural history of spontaneous resolution in immunocompetent children, the mechanism of autoinoculation through scratching, the pain and scarring risks of destructive procedures, and principles of pediatric care that balance expected benefit and harm, select the single management plan that most appropriately aligns lesion number $N$, sites $S$, and anxiety level $A$ to maximize net benefit and minimize harm for this child.\n\nWhich option is most appropriate?\n\nA. No lesion-directed treatment; provide education on contagion and autoinoculation reduction, optimize atopic dermatitis control with emollients and topical anti-inflammatory therapy, avoid traumatizing procedures now, and re-evaluate in $3$ to $6$ months.\n\nB. Initiate a home topical keratolytic (e.g., potassium hydroxide $5\\%$) nightly to all lesions, including the face, to accelerate clearance.\n\nC. Schedule in-office cantharidin application to facial lesions and curettage of trunk and flexural lesions in a single visit to provide rapid clearance.\n\nD. Plan cryotherapy for all lesions over multiple visits with topical anesthetic to overcome anxiety and achieve complete eradication.\n\nE. Start oral cimetidine for $8$ weeks to reduce lesion burden without procedural pain, with no other changes to current care.",
            "solution": "## DERIVATION AND OPTION ANALYSIS\n\nThe problem requires a decision-making process that optimizes the net benefit for the patient by considering the disease characteristics and patient-specific factors. The core principle is *primum non nocere* (first, do no harm), which is particularly salient given the patient's high anxiety and the benign, self-limited nature of the underlying condition.\n\n**Analysis of Patient Factors:**\n1.  **Disease Nature:** Molluscum contagiosum is self-resolving. In an immunocompetent $6$-year-old, spontaneous clearance is the expected outcome, although it may take months to a few years. This lowers the urgency for active, aggressive intervention.\n2.  **Co-morbidity (Atopic Dermatitis):** The presence of atopic dermatitis is critical. The associated pruritus (itching) leads to scratching (excoriation), which is the primary mechanism for autoinoculation (spreading lesions) and can lead to secondary bacterial infection. Therefore, managing the atopic dermatitis is a key component of managing the molluscum.\n3.  **Lesion Burden and Site ($N=36$, $S$ includes face):** The number of lesions is moderate. The facial lesions ($2$) might be of cosmetic concern but also represent an area with a higher risk of scarring from destructive treatments.\n4.  **Patient Anxiety ($A=8/10$):** This factor is a strong contraindication to any painful or frightening procedure. Forcing a child with such high anxiety to undergo procedures like cryotherapy or curettage would cause significant psychological trauma, which constitutes a major harm that likely outweighs the benefit of accelerated lesion clearance.\n\n**Optimal Strategy Synthesis:**\nThe optimal strategy should:\n-   Acknowledge the self-resolving nature of the disease.\n-   Prioritize the minimization of physical and psychological harm.\n-   Address the root cause of lesion spread, which is scratching secondary to atopic dermatitis.\n\nThis leads to a conclusion that a conservative approach focused on comfort, managing the underlying eczema, and patient education is superior to aggressive lesion-directed therapies.\n\n### Option-by-Option Analysis\n\n**A. No lesion-directed treatment; provide education on contagion and autoinoculation reduction, optimize atopic dermatitis control with emollients and topical anti-inflammatory therapy, avoid traumatizing procedures now, and re-evaluate in $3$ to $6$ months.**\n-   **Analysis:** This plan directly aligns with the synthesis above. It correctly identifies molluscum as self-limited and prioritizes avoiding the harm of procedures in a highly anxious child ($A=8/10$). Critically, it includes a plan to optimize atopic dermatitis control, which will reduce pruritus, scratching, and subsequent autoinoculation. Education empowers the family, and planned re-evaluation provides a safety net. This approach maximizes net benefit by actively managing morbidity (itching) while minimizing iatrogenic (treatment-induced) harm.\n-   **Verdict:** **Correct**.\n\n**B. Initiate a home topical keratolytic (e.g., potassium hydroxide $5\\%$) nightly to all lesions, including the face, to accelerate clearance.**\n-   **Analysis:** Topical keratolytics like potassium hydroxide $5\\%$ work by irritating the skin to provoke an immune response. In a patient with atopic dermatitis, the skin barrier is already compromised, and such an irritant is highly likely to cause excessive inflammation, pain, and worsening of the eczema. This could increase itching and scratching, defeating the purpose. Applying an irritant to $36$ lesions, including on the sensitive face, is a poor strategy for this specific patient.\n-   **Verdict:** **Incorrect**.\n\n**C. Schedule in-office cantharidin application to facial lesions and curettage of trunk and flexural lesions in a single visit to provide rapid clearance.**\n-   **Analysis:** This is an extremely aggressive approach. Curettage is a sharp, painful procedure that would be terrifying and traumatic for a child with an anxiety score of $A=8/10$. Cantharidin causes blistering, which can be painful and carries a risk of scarring, particularly on the face. Subjecting this child to such a combination of destructive procedures is a profound violation of the principle to minimize harm.\n-   **Verdict:** **Incorrect**.\n\n**D. Plan cryotherapy for all lesions over multiple visits with topical anesthetic to overcome anxiety and achieve complete eradication.**\n-   **Analysis:** Cryotherapy (freezing) is painful. While a topical anesthetic can dull the sensation, it is often insufficient to eliminate pain, and the procedure itself is frightening. For a child with severe procedural anxiety ($A=8/10$), this remains a highly distressing experience. Multiple visits would mean repeated psychological trauma. Furthermore, cryotherapy carries a significant risk of hypopigmentation (light spots) and scarring, making it a suboptimal choice, especially for facial lesions.\n-   **Verdict:** **Incorrect**.\n\n**E. Start oral cimetidine for $8$ weeks to reduce lesion burden without procedural pain, with no other changes to current care.**\n-   **Analysis:** The efficacy of oral cimetidine for molluscum is highly debated, with many studies showing it is no better than placebo. Prescribing a systemic medication with potential (albeit rare) side effects for a benign, self-resolving condition, especially when its effectiveness is questionable, is not good practice. The plan also specifies \"no other changes,\" meaning it neglects the crucial step of managing the atopic dermatitis, which is a key driver of the patient's symptoms and spread of the lesions.\n-   **Verdict:** **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Interpreting the results of clinical trials is a core skill in evidence-based medicine. Moving beyond statistical significance, clinicians must be able to translate research findings into practical metrics that inform shared decision-making. This practice  guides you through the fundamental derivation of the Number Needed to Treat ($NNT$), a powerful tool for quantifying the absolute benefit of an intervention like cantharidin and communicating its real-world impact.",
            "id": "5171574",
            "problem": "A pediatric dermatology service conducts a randomized, parallel-group clinical trial in children with molluscum contagiosum, comparing topical cantharidin to a bland emollient control. The primary endpoint is complete lesion clearance assessed at a fixed time horizon of $6$ weeks, coded as a binary outcome where $1$ indicates complete clearance and $0$ indicates incomplete clearance. Let $p_{\\mathrm{t}}$ denote the probability of complete clearance at $6$ weeks in the cantharidin arm and let $p_{\\mathrm{c}}$ denote the corresponding probability in the control arm. Using only fundamental definitions from clinical epidemiology, begin with the Bernoulli outcome model and the definition of absolute risk difference as the expected gain in beneficial outcomes per treated patient. From this base, derive the general expression for the Number Needed to Treat (NNT) for a beneficial outcome at a fixed time horizon, expressed in terms of $p_{\\mathrm{t}}$ and $p_{\\mathrm{c}}$, and then evaluate it for $p_{\\mathrm{c}} = 0.50$ and $p_{\\mathrm{t}} = 0.75$ at $6$ weeks. Provide the final NNT as a single real-valued number. No rounding is required.",
            "solution": "The problem asks for the derivation of the Number Needed to Treat (NNT) from fundamental principles and its subsequent evaluation for a specific case.\n\nLet $Y$ be a random variable representing the binary outcome of complete lesion clearance at a fixed time horizon of $6$ weeks. The outcome is coded as $Y=1$ for complete clearance and $Y=0$ for incomplete clearance. This is a Bernoulli trial.\n\nLet $Y_{\\mathrm{t}}$ be the outcome variable for a patient randomized to the treatment arm (cantharidin) and $Y_{\\mathrm{c}}$ be the outcome variable for a patient randomized to the control arm (emollient). Both are Bernoulli random variables.\n\nThe probabilities of complete clearance (a \"success,\" $Y=1$) in the treatment and control arms are given as $p_{\\mathrm{t}}$ and $p_{\\mathrm{c}}$, respectively.\nThe probability distributions are:\n$P(Y_{\\mathrm{t}} = 1) = p_{\\mathrm{t}}$ and $P(Y_{\\mathrm{t}} = 0) = 1 - p_{\\mathrm{t}}$\n$P(Y_{\\mathrm{c}} = 1) = p_{\\mathrm{c}}$ and $P(Y_{\\mathrm{c}} = 0) = 1 - p_{\\mathrm{c}}$\n\nThe expected value of a Bernoulli random variable with success probability $p$ is $E[Y] = 1 \\cdot p + 0 \\cdot (1-p) = p$.\nTherefore, the expected outcome for a patient in the treatment arm is $E[Y_{\\mathrm{t}}] = p_{\\mathrm{t}}$, and for a patient in the control arm is $E[Y_{\\mathrm{c}}] = p_{\\mathrm{c}}$.\n\nThe problem defines the primary measure of effect as the \"expected gain in beneficial outcomes per treated patient\". This is the difference between the expected outcome with treatment and the expected outcome with control. This quantity is formally known as the Absolute Risk Difference (ARD) or Absolute Risk Reduction (ARR).\n$$\n\\text{ARD} = E[Y_{\\mathrm{t}}] - E[Y_{\\mathrm{c}}]\n$$\nSubstituting the expected values, we get:\n$$\n\\text{ARD} = p_{\\mathrm{t}} - p_{\\mathrm{c}}\n$$\nThis expression, $p_{\\mathrm{t}} - p_{\\mathrm{c}}$, represents the excess probability of achieving a beneficial outcome (complete clearance) that is attributable to the treatment. It can be interpreted as the average number of additional successful outcomes gained per patient treated.\n\nThe Number Needed to Treat (NNT) is defined as the expected number of patients who need to receive the treatment for one additional beneficial outcome to occur compared to the control group. If each treated patient contributes an average gain of $\\text{ARD}$, we need to find the number of patients, $N$, such that the total gain equals $1$.\n$$\nN \\times \\text{ARD} = 1\n$$\nSolving for $N$, we find that $N$ is the NNT.\n$$\n\\text{NNT} = \\frac{1}{\\text{ARD}}\n$$\nSubstituting the expression for ARD in terms of the outcome probabilities, we arrive at the general expression for the NNT for a beneficial outcome:\n$$\n\\text{NNT} = \\frac{1}{p_{\\mathrm{t}} - p_{\\mathrm{c}}}\n$$\nThis expression is valid only when $p_{\\mathrm{t}} > p_{\\mathrm{c}}$, which signifies a beneficial treatment. If $p_{\\mathrm{t}} \\le p_{\\mathrm{c}}$, the concept of NNT for a benefit is not meaningful, and one might instead calculate the Number Needed to Harm (NNH).\n\nNow, we evaluate this expression for the given values:\nProbability of clearance in the control arm, $p_{\\mathrm{c}} = 0.50$.\nProbability of clearance in the treatment arm, $p_{\\mathrm{t}} = 0.75$.\n\nFirst, calculate the Absolute Risk Difference (ARD):\n$$\n\\text{ARD} = p_{\\mathrm{t}} - p_{\\mathrm{c}} = 0.75 - 0.50 = 0.25\n$$\nNext, calculate the NNT using the derived formula:\n$$\n\\text{NNT} = \\frac{1}{\\text{ARD}} = \\frac{1}{0.25}\n$$\n$$\n\\text{NNT} = 4\n$$\nThe calculated NNT is $4$. This means that, on average, $4$ children must be treated with topical cantharidin for one additional child to achieve complete clearance of molluscum contagiosum by $6$ weeks, compared to what would have been observed with the bland emollient control.",
            "answer": "$$\\boxed{4}$$"
        },
        {
            "introduction": "Clinical decisions are increasingly influenced by considerations of value and resource allocation. For conditions with multiple management options, such as molluscum contagiosum, it is essential to formally weigh the costs of an intervention against the health benefits it confers. This advanced exercise  introduces you to the principles of health-economic analysis by asking you to compute the Incremental Cost-Effectiveness Ratio (ICER), a key metric used to determine if the additional quality-of-life gained from a therapy justifies its additional cost.",
            "id": "5171546",
            "problem": "A pediatric dermatology clinic is evaluating two management strategies for molluscum contagiosum in 5-year-old children over a fixed horizon of $12$ months. The clinic wants to estimate the incremental cost-effectiveness of cantharidin therapy compared to watchful waiting based on the following scientifically grounded assumptions and data.\n\nFoundational facts and definitions: molluscum contagiosum has a self-limited course with spontaneous clearance, and cantharidin application accelerates lesion resolution in many children. The effectiveness over time can be described using time-to-clearance distributions. The Quality-Adjusted Life Year (QALY) is defined as the time integral of health-related utility over the evaluation horizon, expressed in years.\n\nHorizon and calendaring assumptions: the time horizon is $12$ months, with each month taken to be exactly $30$ days (so $12$ months equals $360$ days). There is no discounting due to the short horizon.\n\nStrategies:\n- Watchful waiting: clearance time $\\tau_{w}$ is exponentially distributed with rate $\\lambda_{w} = 0.08$ per month. Health utility while lesions are present is $u_{a} = 0.97$. When lesions are resolved, utility is $u_{r} = 1.00$. Costs include an initial diagnostic visit $C_{\\text{init}} = 90$ dollars, one scheduled follow-up visit at month $6$ with cost $C_{\\text{follow}} = 60$ dollars, and emollients costing $c_{e} = 5$ dollars per month while lesions remain present.\n- Cantharidin: clearance time $\\tau_{c}$ is exponentially distributed with rate $\\lambda_{c} = 0.30$ per month. Utility while lesions are present is $u_{a} = 0.97$; when resolved, utility is $u_{r} = 1.00$. Each cantharidin application causes blistering for $d = 3$ days with an additional utility decrement of $\\delta = 0.05$ during those $d$ days. Cantharidin is applied at the start of each month in which lesions are still present; if lesions resolve, no further applications occur. Costs include the same initial diagnostic visit $C_{\\text{init}} = 90$ dollars and a per-application cost of $c_{a} = 120$ dollars. There are no other scheduled follow-up costs.\n\nModeling conventions:\n- Let $S_{x}(t)$ denote the probability that lesions are still present at time $t$ months under strategy $x \\in \\{w, c\\}$, where $S_{x}(t) = \\exp(-\\lambda_{x} t)$ for an exponential clearance process.\n- The expected number of months with lesions present over the $12$-month horizon is the expected truncated time $E[\\min(\\tau_{x},12)]$, where $\\tau_{x}$ is measured in months.\n- Under cantharidin, applications occur at month starts $m = 0, 1, \\dots, 11$ whenever lesions are still present. The expected number of applications equals $\\sum_{m=0}^{11} S_{c}(m)$.\n- QALYs for each strategy over $12$ months are the sum of utility-weighted months divided by $12$ to express in years. The blister-related disutility under cantharidin should be counted for its duration in days and converted to years using the $360$-day convention.\n\nTask: Using the above assumptions and data, compute the incremental cost-effectiveness ratio of cantharidin compared to watchful waiting over $12$ months, defined as the incremental cost divided by the incremental QALYs gained by cantharidin over watchful waiting. Express the final result in dollars per Quality-Adjusted Life Year (QALY). Round your final ICER to four significant figures. Do not include units in your final boxed answer.",
            "solution": "The task is to compute the incremental cost-effectiveness ratio (ICER) of cantharidin therapy relative to watchful waiting for pediatric molluscum contagiosum over a $12$-month horizon.\n\nThe ICER is defined as:\n$$\n\\text{ICER} = \\frac{\\Delta C}{\\Delta Q} = \\frac{E[\\text{Cost}_{\\text{c}}] - E[\\text{Cost}_{\\text{w}}]}{E[\\text{QALY}_{\\text{c}}] - E[\\text{QALY}_{\\text{w}}]}\n$$\nwhere the subscripts 'c' and 'w' denote the cantharidin and watchful waiting strategies, respectively. We will calculate the expected costs and expected Quality-Adjusted Life Years (QALYs) for each strategy.\n\nThe given parameters are:\n- Time horizon, $T = 12$ months\n- Watchful waiting clearance rate, $\\lambda_w = 0.08$ per month\n- Cantharidin clearance rate, $\\lambda_c = 0.30$ per month\n- Utility with active lesions, $u_a = 0.97$\n- Utility when resolved, $u_r = 1.00$\n- Cantharidin blister utility decrement, $\\delta = 0.05$\n- Cantharidin blister duration, $d = 3$ days\n- Initial visit cost, $C_{\\text{init}} = 90$ dollars\n- Watchful waiting follow-up cost, $C_{\\text{follow}} = 60$ dollars\n- Watchful waiting emollient cost, $c_e = 5$ dollars per month\n- Cantharidin application cost, $c_a = 120$ dollars\n\nThe survival function, representing the probability of lesions still being present at time $t$ months, is $S_x(t) = \\exp(-\\lambda_x t)$.\n\n**1. Analysis of Watchful Waiting Strategy (w)**\n\nFirst, we calculate the expected number of months with lesions present over the $12$-month horizon, denoted $E_w$. This is the expected value of the clearance time $\\tau_w$ truncated at $T=12$ months, given by the integral of the survival function.\n$$\nE_w = E[\\min(\\tau_w, T)] = \\int_{0}^{T} S_w(t) \\,dt = \\int_{0}^{12} \\exp(-\\lambda_w t) \\,dt\n$$\n$$\nE_w = \\left[ -\\frac{1}{\\lambda_w} \\exp(-\\lambda_w t) \\right]_0^{12} = \\frac{1}{\\lambda_w} (1 - \\exp(-12\\lambda_w))\n$$\nSubstituting the values $\\lambda_w = 0.08$:\n$$\nE_w = \\frac{1}{0.08} (1 - \\exp(-12 \\times 0.08)) = 12.5 (1 - \\exp(-0.96)) \\approx 7.7138 \\text{ months}\n$$\n\nThe expected cost for watchful waiting, $E[\\text{Cost}_w]$, is the sum of the fixed initial and follow-up visit costs, plus the variable cost of emollients, which depends on the expected duration of lesions.\n$$\nE[\\text{Cost}_w] = C_{\\text{init}} + C_{\\text{follow}} + c_e \\times E_w\n$$\n$$\nE[\\text{Cost}_w] = 90 + 60 + 5 \\times 7.713838... = 150 + 38.56919... \\approx 188.57 \\text{ dollars}\n$$\n\nThe expected QALYs, $E[\\text{QALY}_w]$, are calculated by integrating the expected utility over the $12$-month horizon and expressing it in years. The total utility-months are the sum of utility during the time with lesions ($E_w$) and the time without lesions ($T - E_w$).\n$$\nE[\\text{QALY}_w] = \\frac{1}{12} \\left( u_a E_w + u_r (12 - E_w) \\right) = u_r + \\frac{u_a - u_r}{12} E_w\n$$\n$$\nE[\\text{QALY}_w] = 1.00 + \\frac{0.97 - 1.00}{12} \\times 7.713838... = 1 - 0.0025 \\times 7.713838... \\approx 0.980715 \\text{ QALYs}\n$$\n\n**2. Analysis of Cantharidin Strategy (c)**\n\nFirst, we calculate the expected number of cantharidin applications, $N_c$. Applications occur at the start of each month ($m=0, 1, ..., 11$) if lesions are present. The expected number of applications is the sum of the probabilities of being uncured at the start of each month.\n$$\nN_c = \\sum_{m=0}^{11} S_c(m) = \\sum_{m=0}^{11} \\exp(-\\lambda_c m)\n$$\nThis is a finite geometric series with $12$ terms, first term $a=1$, and common ratio $r = \\exp(-\\lambda_c)$.\n$$\nN_c = \\frac{1 - (\\exp(-\\lambda_c))^{12}}{1 - \\exp(-\\lambda_c)} = \\frac{1 - \\exp(-12\\lambda_c)}{1 - \\exp(-\\lambda_c)}\n$$\nSubstituting $\\lambda_c = 0.30$:\n$$\nN_c = \\frac{1 - \\exp(-12 \\times 0.30)}{1 - \\exp(-0.30)} = \\frac{1 - \\exp(-3.6)}{1 - \\exp(-0.3)} \\approx 3.75317 \\text{ applications}\n$$\n\nThe expected cost for the cantharidin strategy, $E[\\text{Cost}_c]$, includes the initial visit cost and the cost of the expected number of applications.\n$$\nE[\\text{Cost}_c] = C_{\\text{init}} + c_a \\times N_c\n$$\n$$\nE[\\text{Cost}_c] = 90 + 120 \\times 3.75317... = 90 + 450.3804... \\approx 540.38 \\text{ dollars}\n$$\n\nTo calculate the QALYs, we first need the expected number of months with lesions, $E_c$.\n$$\nE_c = \\int_{0}^{12} \\exp(-\\lambda_c t) \\,dt = \\frac{1}{\\lambda_c} (1 - \\exp(-12\\lambda_c))\n$$\n$$\nE_c = \\frac{1}{0.30} (1 - \\exp(-3.6)) \\approx 3.24249 \\text{ months}\n$$\n\nThe expected QALYs for cantharidin, $E[\\text{QALY}_c]$, are calculated similarly to watchful waiting but must also account for the disutility from blistering. The total QALY loss from blistering is the expected number of applications, $N_c$, multiplied by the disutility per application, $\\delta$, and the duration, $d$, converted to years (using the $360$-day year convention).\n$$\n\\text{QALY loss from blistering} = \\frac{N_c \\times d \\times \\delta}{360}\n$$\nThe total expected QALYs are:\n$$\nE[\\text{QALY}_c] = \\left( u_r + \\frac{u_a - u_r}{12} E_c \\right) - \\frac{N_c d \\delta}{360}\n$$\n$$\nE[\\text{QALY}_c] = \\left( 1.00 + \\frac{0.97-1.00}{12} \\times 3.24249... \\right) - \\frac{3.75317... \\times 3 \\times 0.05}{360}\n$$\n$$\nE[\\text{QALY}_c] = (1 - 0.0025 \\times 3.24249...) - \\frac{0.562975...}{360}\n$$\n$$\nE[\\text{QALY}_c] \\approx 0.991894 - 0.001564 \\approx 0.990330 \\text{ QALYs}\n$$\n\n**3. Incremental Cost-Effectiveness Ratio (ICER)**\n\nNow we compute the incremental cost ($\\Delta C$) and incremental QALYs ($\\Delta Q$).\n$$\n\\Delta C = E[\\text{Cost}_c] - E[\\text{Cost}_w] \\approx 540.3804 - 188.5692 = 351.8112 \\text{ dollars}\n$$\n$$\n\\Delta Q = E[\\text{QALY}_c] - E[\\text{QALY}_w] \\approx 0.990330 - 0.980715 = 0.009615 \\text{ QALYs}\n$$\n\nFinally, the ICER is the ratio of incremental cost to incremental QALYs.\n$$\n\\text{ICER} = \\frac{\\Delta C}{\\Delta Q} \\approx \\frac{351.8112}{0.009615} \\approx 36591.74 \\text{ dollars per QALY}\n$$\n\nRounding the final result to four significant figures gives $36590$.",
            "answer": "$$\\boxed{36590}$$"
        }
    ]
}